Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children of either sexes, aged 0-12 years~* Diagnosis of mono- or bilateral primary congenital glaucoma~* IOP greater than or equal to 22 mmHg and lower than 27 mmHg~* Only one previous ocular hypotensive surgical procedure for treatment of glaucoma among the following: goniotomy, trabeculotomy, trabeculotomy with adjunct of mitomycin C) (only for medical treatment at least one month before)~* Parent informed consent to data processing (at registration)~* Parent informed consent before any study procedure~Exclusion Criteria:~* Secondary glaucoma (Sturge-Weber syndrome, type I neurofibromatosis, retinoblastoma, steroid-induced glaucoma, etc.)~* Presence of concomitant abnormalities of the anterior segment of the eye (cataract, iridocorneal dysgenesia, congenital uveal ectropion uvea, etc.)~* Previous treatment with the study drugs~* Presence of concomitant systemic diseases (asthma, hypertension, cardiac disease, renal failure, etc.) that needs treatment with drugs, that could influence IOP (steroids, beta-blockers, angiotensin-converting-enzyme inhibitor -inhibitors diuretics, etc.)~* Abnormalities of the cornea that could influence IOP readings (marked cornea edema)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Latanoprost, Dorzolamide (Type: OTHER): According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.

Based on this trial design, predict the completion outcome and termination type (if applicable).